We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.46%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$17B
AUM Growth
+$1.34B
(+8.6%)
Cap. Flow
-$377M
Cap. Flow
% of AUM
-2.22%
Top 10 Holdings %
Top 10 Hldgs %
15.59%
Holding
389
New
43
Increased
82
Reduced
143
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$204M |
| 2 |
AbbVie
ABBV
|
+$141M |
| 3 |
TYC
TYCO INTL PLC COM SHS (IRL)
TYC
|
+$130M |
| 4 |
Caterpillar
CAT
|
+$125M |
| 5 |
Johnson Controls International
JCI
|
+$90.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPHM
VIROPHARMA INC
VPHM
|
+$188M |
| 2 |
Merck
MRK
|
+$155M |
| 3 |
Apple
AAPL
|
+$155M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$131M |
| 5 |
Bread Financial
BFH
|
+$96.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.01% |
| 2 | Industrials | 15.63% |
| 3 | Consumer Discretionary | 14.7% |
| 4 | Technology | 8.94% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Idexx Laboratories
IDXX
$46.4B
| $108M | 0.64% |
2,036,556
+170,816
| +9% | +$8.99M |
|
|
JAH
52
DELISTED
JARDEN CORPORATION
JAH
| $108M | 0.63% |
2,632,886
-105,037
| -4% | -$3.81M |
|
53
Ecolab
ECL
$79.7B
| $107M | 0.63% |
1,026,965
+323,485
| +46% | +$33.6M |
|
54
CSX Corp
CSX
$94.5B
| $104M | 0.61% |
10,885,938
-194,571
| -2% | -$1.74M |
|
|
MWIV
55
DELISTED
MWI VETERINARY SUPPLY, INC.
MWIV
| $104M | 0.61% |
613,909
+227,100
| +59% | +$37.7M |
|
56
Best Buy
BBY
$18.2B
| $101M | 0.59% |
2,526,040
+455,020
| +22% | +$18.7M |
|
|
WCC
57
WESCO International
WCC
$18.2B
| $100M | 0.59% |
1,103,460
+149,865
| +16% | +$12.5M |
|
58
Suncor Energy
SU
$76.1B
| $99.5M | 0.59% |
2,839,852
+357,565
| +14% | +$12.6M |
|
|
59
Johnson Controls International
JCI
$93.1B
| $98.9M | 0.58% |
+1,840,458
| New | +$90.6M |
|
|
TSS
60
DELISTED
Total System Services, Inc.
TSS
| $96.4M | 0.57% |
2,897,060
+58,360
| +2% | +$1.79M |
|
61
Raymond James Financial
RJF
$34.3B
| $94.7M | 0.56% |
2,722,365
+591,975
| +28% | +$18.3M |
|
|
BEAV
62
DELISTED
B/E Aerospace Inc
BEAV
| $93.2M | 0.55% |
1,479,291
-37,474
| -2% | -$2.24M |
|
63
TransDigm Group
TDG
$71.3B
| $93M | 0.55% |
577,427
-21,100
| -4% | -$3.15M |
|
|
IHS
64
DELISTED
IHS INC CL-A COM STK
IHS
| $91.9M | 0.54% |
767,649
+178,280
| +30% | +$20.2M |
|
65
Lincoln Electric
LECO
$15.1B
| $91.3M | 0.54% |
1,280,460
+698,020
| +120% | +$49M |
|
66
Lennar Class A
LEN
$21B
| $86.2M | 0.51% |
2,288,688
-67,672
| -3% | -$2.28M |
|
67
Las Vegas Sands
LVS
$29.8B
| $85.4M | 0.5% |
1,082,693
-20,202
| -2% | -$1.45M |
|
|
QLIK
68
DELISTED
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
| $84.8M | 0.5% |
3,184,596
+201,010
| +7% | +$5.55M |
|
69
Generac Holdings
GNRC
$12.9B
| $83.9M | 0.49% |
+1,481,440
| New | +$72.4M |
|
70
NVR
NVR
$16.8B
| $82M | 0.48% |
79,952
+11,903
| +17% | +$11.3M |
|
71
PACCAR
PCAR
$71.6B
| $77.4M | 0.46% |
1,963,304
-33,654
| -2% | -$1.27M |
|
72
VF Corp
VFC
$5.99B
| $77.1M | 0.45% |
+1,313,751
| New | +$68.5M |
|
73
eBay
EBAY
$48.7B
| $76.8M | 0.45% |
3,326,314
-39,347
| -1% | -$871K |
|
74
Acadia Pharmaceuticals
ACAD
$4.65B
| $74.2M | 0.44% |
2,971,041
+910,490
| +44% | +$21.5M |
|
|
ALEX
75
DELISTED
Alexander & Baldwin
ALEX
| $72.9M | 0.43% |
1,746,875
+159,710
| +10% | +$6.13M |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, Westfield Capital Management held 389 positions worth $17B, up 8.6% from $15.6B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Westfield Capital Management's Q4 2013 filing shows 43 new, 82 increased, 143 reduced and 65 closed positions. Its largest new stake was Teva Pharmaceuticals: 5,174,039 shares worth $207M. The largest sale was VIROPHARMA INC, an estimated $188M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.
- Westfield Capital Management's largest Q4 2013 buy was Teva Pharmaceuticals: 5,174,039 shares worth $207M.
- Westfield Capital Management added most to AbbVie in Q4 2013, an estimated $141M increase.
- Westfield Capital Management's biggest Q4 2013 reduction was VIROPHARMA INC, cutting an estimated $188M.
- Westfield Capital Management fully exited Citrix Systems Inc in Q4 2013, selling an estimated $131M.
- Westfield Capital Management's ten largest holdings make up 16% of its $17B portfolio in Q4 2013.
- Westfield Capital Management opened 43 new positions and closed 65 in Q4 2013.
- Westfield Capital Management's portfolio value rose 8.6% quarter-over-quarter to $17B.
Based on Westfield Capital Management's 13F filing for Q4 2013, filed 7 Feb 2014.